A 68-year-old man has been diagnosed with benign prostatic hyperplasia (BPH). Which is the most significant pathophysiology that contributes to the development of this condition? a) Decreased testosterone production b) Increased insulin-like growth factor c) Increased estrogen levels d) Reduced blood supply
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
I now have comprehensive textbook content. The answer is clear.
Answer: (c) Increased estrogen levels
The correct answer is c) Increased estrogen levels.
Pathophysiology of BPH — Key Mechanisms
BPH development is driven by a complex interplay of androgens and estrogens. Here is how each option stands:
✅ (c) Increased Estrogen Levels — The Most Significant Answer
As men age, serum estrogen levels rise both absolutely and relative to testosterone. This shift in the androgen-to-estrogen ratio is the central hormonal driver of BPH:
- Stromal sensitization: Estrogen "sensitizes" the aging prostate to the effects of androgens by upregulating androgen receptors (AR) in stromal cells — even modest DHT levels then produce a greater proliferative response.
- Stromal stimulation: Estrogen (acting via estrogen receptor α on stromal cells) stimulates collagen deposition and upregulates growth factors (FGF-2, FGF-7), promoting the stromal hyperplasia that characterizes BPH.
- Intraprostatic levels: Men with larger BPH volumes consistently show higher circulating estradiol. In the Olmsted County cohort, serum estradiol correlated positively with prostate volume even after adjusting for age.
- Animal evidence: In the dog model, estrogen acts synergistically with androgens to produce BPH and is required for the induction of the AR.
"Serum estrogen levels increase in men with age, absolutely or relative to testosterone levels. There is also suggestive evidence that intraprostatic levels of estrogen are increased in men with BPH." — Campbell-Walsh-Wein Urology, 12th ed.
Why the Other Options Are Incorrect
| Option | Verdict | Reason |
|---|---|---|
| (a) Decreased testosterone | ❌ | Testosterone actually decreases with age. However, this is not the driver of BPH. BPH occurs because of increased sensitivity to androgens (via DHT and estrogen-mediated AR upregulation), not because of more testosterone. Men castrated before puberty do not develop BPH. |
| (b) Increased insulin-like growth factor (IGF) | ❌ | Growth factors (IGF, FGF, EGF, TGF) play a secondary paracrine/autocrine role in prostatic cell proliferation but are downstream of hormonal signaling — not the primary/most significant pathophysiologic mechanism. |
| (d) Reduced blood supply | ❌ | Vascular changes (e.g., from diabetes or metabolic syndrome) may be a risk factor for BPH, but reduced blood supply is not a recognized primary pathophysiologic mechanism. |
The Full Hormonal Picture
The fundamental model is:
- With aging, testosterone falls but is converted to DHT (by 5α-reductase type 2 in stromal cells) — DHT is a far more potent androgen than testosterone and drives prostatic growth.
- Simultaneously, estrogen rises and upregulates AR in stroma, amplifying the cellular response to even lower DHT levels.
- The result is disproportionate stromal and glandular hyperplasia in the transition zone → urethral compression → LUTS.
The increased estrogen (option c) is identified as the most significant pathophysiologic contributor because it sets the stage for androgen-driven growth by sensitizing the prostate and is the hallmark hormonal change of aging men who develop BPH.
— Campbell-Walsh-Wein Urology, Chapter 144 (BPH: Etiology, Pathophysiology, Epidemiology, and Natural History)
This is a shared conversation. Sign in to Orris to start your own chat.